Jacob Bell

@realJacobBell

Dad says I'm not an effective communicator. Reporter . Formerly , , . 99% Ashley Katchadourian, 1% hot gas.

Washington, DC
Vrijeme pridruživanja: prosinac 2011.

Tweetovi

Blokirali ste korisnika/cu @realJacobBell

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @realJacobBell

  1. Prikvačeni tweet
    25. lis 2019.

    Ever notice how biotechs like and are asked often about M&A, but not so much? I took a deep dive into why that is, and whether recent challenges to Regeneron's top-selling drug could change the company's dealmaking track record.

    Poništi
  2. proslijedio/la je Tweet
    Poništi
  3. prije 9 sati
    Poništi
  4. prije 11 sati

    Btw, that now 24% stock increase equates to more than $12B in added value to 's market cap.

    Poništi
  5. prije 11 sati

    From the text: "ORDERED that claims 1–20 of U.S. Patent No. 8,399,514 B2 are not determined to be unpatentable ..."

    Prikaži ovu nit
    Poništi
  6. prije 11 sati

    PTAB knocks down challenge against Tecfidera patents. Biogen shares up 23% right now

    Prikaži ovu nit
    Poništi
  7. 4. velj

    says there is a sense of urgency to do BD. What do you think?

    Poništi
  8. 4. velj

    RBC: "Among HCV products, Harvoni was generally in-line while Epclusa missed ($465M) despite strong Rx, perhaps suggesting continued price compression in the space. Yescarta continues to show very gradual growth ($122M) though we believe has become a lesser investor focus."

    Poništi
  9. proslijedio/la je Tweet
    4. velj

    Impairment charge took on Kite assets tied to treatment of indolent NHL, whereas in 2018 it was related to a specific asset, the anti-BCMA product KTE-585:

    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    4. velj
    Poništi
  11. 4. velj

    up more than 3% in afterhours trading on Q4 results. Co. reports total revenue of $244M for Q4 and $788M for FY19, up 86% and 75% year over year. Co. had cash/cash equivalents/marketable securities of $970M as of Dec. 31

    Poništi
  12. 3. velj

    Q2 earnings show its oral and specialty delivery segment was the only segment that didn't grow YoY. Co. says it was due to respiratory and ophthalmic volume declines related to delayed product approvals. Co. expects these delays will impact the next few quarters as well.

    Poništi
  13. proslijedio/la je Tweet
    3. velj

    announcing tonight it's making its adjuvant technology available to groups working w/ CEPI to develop a coronavirus vaccine. Univ. of Queensland the first to formalize an agreement, GSK says. + NIH, CureVac and Inovio the other 3 groups working with CEPI.

    Poništi
  14. 2. velj

    It’s hard to find positive news, yet this week we confirmed in the Physical music video that Dua Lipa can pull off any color

    Poništi
  15. proslijedio/la je Tweet
    31. sij

    Take a gander at this 👀👀👀 Thanks to painstaking investigative journalism by a sharp young reporter ( & alum ), a bill that would keep court information public is working its way through the Maryland General Assembly .

    Poništi
  16. 1. velj

    *CORRECTION: $80/pill

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    31. sij

    withdrawing EU application for approval of Opdivo/Yervoy combo in first-line lung cancer. The application was based on the CM-227 study results that the co. is using for its FDA application (PDUFA May 15)

    Prikaži ovu nit
    Poništi
  18. 31. sij

    announces its new migraine drug Reyvow (lasmiditan) is now available to patients. Co. tells me the list price is $80/dose

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    31. sij

    I caught up with yesterday to learn why the company's risking its bottom line to increase public transit ridership in Boston.

    Prikaži ovu nit
    Poništi
  20. 31. sij

    *the EDGAR search box. See! I told y’all today was bad

    Prikaži ovu nit
    Poništi
  21. 31. sij

    Featuring interviews with , Steven Paul of , Ted Dawson of , Paul Matteis of and Phil Nadeau

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·